955095-50-8
Chemical Structure
Azeloprazole potassium
- CAS No.: 955095-50-8
- Formula:C22H27KN3O4S
- Molecular Weight:468.63
IUPAC Name: 2-(((4-((2,2-dimethyl-1,3-dioxan-5-yl)methoxy)-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole, potassium salt
InChIKey: DWLDWMDXNMSMSC-UHFFFAOYSA-N
SMILES: S(CC1=C(C)C(OCC2COC(C)(C)OC2)=C(C)C=N1)(=O)C=3NC=4C(N3)=CC=CC4.[K]
Biological Activity: Azeloprazole potassium is an orally active proton pump inhibitor. Azeloprazole potassium irreversibly binds to and blocks the proton pump (H+/K+-ATPase) on parietal cells, thereby inhibiting gastric acid secretion. Azeloprazole potassium is primarily metabolized by the CYP3A4 enzyme, and its pharmacokinetics and acid-suppressive effects are independent of CYP2C19 activity. Azeloprazole potassium can be used for research on acid-related diseases such as reflux esophagitis and gastroesophageal reflux disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Azeloprazole potassium | Azeloprazole potassium is an orally active proton pump inhibitor. Azeloprazole potassium irreversibly binds to and blocks the proton pump (H+/K+-ATPase) on parietal cells, thereby inhibiting gastric acid secretion. Azeloprazole potassium is primarily metabolized by the CYP3A4 enzyme, and its pharmacokinetics and acid-suppressive effects are independent of CYP2C19 activity. Azeloprazole potassium can be used for research on acid-related diseases such as reflux esophagitis and gastroesophageal reflux disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Srebro J, et al. Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives. Pharmaceutics. 2022 Sep 25;14(10):2043.
- [2]. Kinoshita Y, et al. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. Current therapeutic research, clinical and experimental. 2018;88:26-34.
- [3]. Simadibrata DM, et al. Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?. Expert opinion on investigational drugs. 2024 Oct;33(10):1009-1018.
- [4]. Hunt RH, et al. Potent Acid Suppression with PPIs and P-CABs: What's New?. Current treatment options in gastroenterology. 2018 Dec;16(4):570-590.
